Barbiturates and Pregnancy: Risks to Fetal Development
Barbiturates are sedative-hypnotics with high addiction potential and serious teratogenic risks.
Fetal Risks
- Congenital malformations: Cardiac defects, neural tube defects, cleft lip/palate, microcephaly.
- Growth restriction: Low birth weight, IUGR.
- Neurodevelopmental: Cognitive deficits, learning disabilities, behavioral issues.
- Neonatal withdrawal: Tremors, hyperreflexia, seizures, feeding difficulty, irritability (may last weeks).
- Respiratory depression: At delivery if mother recently dosed.
- Stillbirth: Increased risk with chronic use.
Mechanism
Barbiturates cross placenta, accumulate in fetal tissue, and induce hepatic enzymes (altering steroid metabolism). Chronic use depletes folate.
Clinical Guidance
- Avoid in pregnancy; use safer alternatives (e.g., for epilepsy: levetiracetam, lamotrigine).
- If already pregnant: Do not stop abruptly—risk of maternal/fetal withdrawal seizures. Taper under specialist supervision.
- High-dose folate (4 mg/day) if continuation unavoidable.
- Multidisciplinary care (OB, neurology, psychiatry, neonatology).
Preconception counseling is ideal for medication optimization.
Bulimia - Related Articles
- Thyroid Tests and Bulimia: Understanding the Connection
- Understanding Hot Flashes: Causes, Symptoms & Relief
- Burp Odor: Gut Microbiome, Diet, and When to Worry
- A Day in the Life with Bulimia Nervosa: Typical Patterns
- Bulimia Nervosa: Symptoms, Health Risks, and Treatment Options
- Diphtheria Risk Groups: Unvaccinated, Immunocompromised, Travelers
- Bulimia Nervosa & Dopamine: The Neurobiology of Binge-Purge Cycles
